A Phase 4 interventional study of Nebulized furosemide and Intravenous furosemide in Pulmonary Edema, sponsored by Federal Government Polyclinic - Post Graduate Medical Institute (FGPC-PGMI). Not yet recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 94 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Federal Government Polyclinic - Post Graduate Medical Institute (FGPC-PGMI) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled trial compares intravenous furosemide alone with intravenous plus nebulized furosemide in adults with acute pulmonary edema. The main outcome is the change in peripheral oxygen saturation (SpO2) from baseline, and the secondary outcome is the change in dyspnea severity on a 0-10 visual analogue scale. The trial will test whether adding nebulized furosemide to standard intravenous furosemide gives additional benefit.
Pulmonary edema is a medical emergency in which fluid collects in the alveolar spaces, impairing gas exchange and causing respiratory distress. Intravenous furosemide is the mainstay of treatment but may cause hypotension, electrolyte imbalance and renal dysfunction. Nebulized furosemide delivers the drug directly to the lungs and may improve dyspnea and oxygenation through local effects. Most available studies have tested nebulized furosemide as an alternative to intravenous therapy rather than as an adjunct, so it remains unclear whether the combination offers added benefit over intravenous furosemide alone.
Methods: A randomized controlled trial will be conducted in the Department of Medicine, Federal Government Polyclinic Hospital, Islamabad, over 6 months after ethical approval, using non-probability consecutive sampling. A total of 130 patients (65 per group) will be enrolled. Sample size was calculated with the WHO formula for two means (alpha 0.05, power 80%, SD 1.5, expected difference 0.7) based on Barzegari et al. (2021). After written informed consent, baseline demographics, vital signs, SpO2 and dyspnea VAS score will be recorded. All patients will receive standard initial care with oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg. Patients will be randomized 1:1 using a computer-generated sequence with sequentially numbered, opaque, sealed envelopes. Group A will receive intravenous furosemide 1 mg/kg plus nebulized furosemide 40 mg in 4 ml 0.9% saline, and Group B will receive intravenous furosemide 1 mg/kg alone. SpO2 and dyspnea VAS will be recorded at baseline and at 30, 60 and 120 minutes after intervention.
Statistical analysis: Data will be analyzed in SPSS version 23. Continuous variables will be presented as mean and standard deviation. Between-group comparison of change from baseline in SpO2 and VAS will be done with the independent samples t-test, or the Mann-Whitney U test for non-normal data. Baseline SpO2, baseline dyspnea score, oxygen flow rate, use of nitrates or morphine and underlying cardiac function will be recorded as potential confounders. A p-value below 0.05 will be considered significant.
126 studies on the registry are indexed under Pulmonary Edema; 27 are open to participants now.
This study's planned enrollment of 130 is above the median of 65 across 62 interventional studies indexed under Pulmonary Edema.
Browse Pulmonary Edema studies →This is the only study on the registry with Federal Government Polyclinic - Post Graduate Medical Institute (FGPC-PGMI) as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous furosemide 1 mg/kg slow push over 5 minutes plus nebulized furosemide 40 mg diluted in 4 ml 0.9% saline over 15 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg).
Drug: Nebulized furosemide · Drug: Intravenous furosemide
Intravenous furosemide 1 mg/kg slow push over 5 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg).
Drug: Intravenous furosemide
Furosemide 40 mg diluted in 4 ml 0.9% saline given by jet nebulizer over 15 minutes.
Also known as: Lasix
Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.
Also known as: Lasix
Change in peripheral oxygen saturation (SpO2)
SpO2 (%) measured with a calibrated pulse oximeter; change from baseline will be compared between groups.
Time frame: Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)
Change in dyspnea severity on Visual Analogue Scale (VAS)
Patient-rated breathlessness on a 0-10 VAS (0 = no breathlessness, 10 = worst breathlessness); change from baseline will be compared between groups.
Time frame: Baseline, 30, 60 and 120 minutes after intervention
Plan to share: No
Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.